| The PRISMA 2020 statement: an updated guideline for reporting systematic reviews | BMJ, The | 2021 | 4.5K |
| PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews | BMJ, The | 2021 | 666 |
| The PRISMA 2020 statement: an updated guideline for reporting systematic reviews | Systematic Reviews | 2021 | 513 |
| The PRISMA 2020 statement: An updated guideline for reporting systematic reviews | International Journal of Surgery | 2021 | 461 |
| The PRISMA 2020 statement: An updated guideline for reporting systematic reviews | PLoS Medicine | 2021 | 286 |
| A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 | New England Journal of Medicine | 2021 | 203 |
| The PRISMA 2020 statement: An updated guideline for reporting systematic reviews | Journal of Clinical Epidemiology | 2021 | 201 |
| Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors | Clinical Infectious Diseases | 2021 | 90 |
| Trained immunity, tolerance, priming and differentiation: distinct immunological processes | Nature Immunology | 2021 | 85 |
| Impella RP versus pharmacologic vasoactive treatment in profound cardiogenic shock due to right ventricular failure: Unloading and end-organ perfusion in a large animal model | European Heart Journal: Acute Cardiovascular Care | 2021 | 78 |
| Admission biomarkers among patients with acute myocardial-infarction related cardiogenic shock with or without out-of-hospital cardiac arrest | European Heart Journal: Acute Cardiovascular Care | 2021 | 78 |
| OTEH-3. Targeted Gene-Expression analysis during malignant transformation in primary and secondary malignant meningioma | Neuro-Oncology Advances | 2021 | 78 |
| OTEH-4. Deeper insight into intratumoral heterogeneity by MRI and PET-guided stereotactic biopsies from glioblastoma patients | Neuro-Oncology Advances | 2021 | 78 |
| Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial | EClinicalMedicine | 2021 | 60 |
| Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study | Lancet Infectious Diseases, The | 2021 | 58 |
| EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines | Allergy: European Journal of Allergy and Clinical Immunology | 2021 | 54 |
| Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial | Clinical Breast Cancer | 2021 | 52 |
| Liver cirrhosis | Lancet, The | 2021 | 50 |
| The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria | Allergy: European Journal of Allergy and Clinical Immunology | 2021 | 50 |
| Comparison of 16 Serological SARS-CoV-2 Immunoassays in 16 Clinical Laboratories | Journal of Clinical Microbiology | 2021 | 47 |
| Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial | Lancet, The | 2021 | 47 |
| Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial | JAMA - Journal of the American Medical Association | 2021 | 46 |
| EAACI guideline: Preventing the development of food allergy in infants and young children (2020 update) | Pediatric Allergy and Immunology | 2021 | 46 |
| COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper | Allergy: European Journal of Allergy and Clinical Immunology | 2021 | 46 |
| Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study | Lancet, The | 2021 | 45 |
